journal
MENU ▼
Read by QxMD icon Read
search

Cancer

journal
https://www.readbyqxmd.com/read/29323704/reply-to-the-reply-to-the-letter-on-the-cost-effectiveness-of-human-papillomavirus-in-punjab-further-distorts-the-scientific-record
#1
LETTER
Shankar Prinja, Pankaj Bahuguna, Dharmjeet Singh Faujdar, Gaurav Jyani, Radhika Srinivasan, Sushmita Ghoshal, Vanita Suri, Mini P Singh, Rajesh Kumar
No abstract text is available yet for this article.
January 11, 2018: Cancer
https://www.readbyqxmd.com/read/29316326/orthopedia-homeobox-is-preferentially-expressed-in-typical-carcinoids-of-the-lung
#2
Krisztina Z Hanley, Zachary J Dureau, Cynthia Cohen, Dong M Shin, Taofeek K Owonikoko, Gabriel L Sica
BACKGROUND: Twenty-seven percent of neuroendocrine tumors (NETs) are associated with distant metastases, and in some patients, the primary site is unknown. Orthopedia homeobox protein (OTP) has been described as a useful marker for lung carcinoids (LCs) and for separating low-grade typical carcinoids (TCs) from intermediate-grade atypical carcinoids (ACs) in resection specimens. This study evaluated OTP, thyroid transcription factor 1 (TTF-1), and Ki-67 expression in fine-needle aspiration (FNA) samples of various NETs...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29316324/advanced-practitioner-in-anatomic-pathology-the-time-has-come
#3
EDITORIAL
Brenda J Sweeney, David C Wilbur
No abstract text is available yet for this article.
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29316317/cytotechnologists-as-coinvestigators-in-anatomical-pathology-research
#4
Karla J Kopp, Marie R Passow, Kristina M Del Rosario, Michael R Christensen, John W O'Shaughnessy, Mary K Bartholet, Mary E Francis, Thomas J Flotte
BACKGROUND: The amount of time available to pathologists with which to perform research is becoming limited due to an increasing manpower shortage in pathology, decreased reimbursement, and increased workload. This is occurring at the same time as demands escalate for pathologists to develop new companion tests, correlate the molecular findings with traditional methods, and assist in the development of individualized medicine. This study examined whether cytotechnologists may be integrated into a research team that uses their expertise in understanding pathology and clinical disease to provide interpretations of experiments that traditionally were performed by pathologists...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315535/chinese-and-south-asian-ethnicity-immigration-status-and-clinical-cancer-outcomes-in-the-ontario-cancer-system
#5
James K R Stevenson, Matthew C Cheung, Craig C Earle, Hadas D Fischer, Ximena Camacho, Refik Saskin, Baiju R Shah, Peter C Austin, Simron Singh
BACKGROUND: In the United States, certain minority groups have been shown to have inferior cancer outcomes compared with the white majority population. However, to the authors' knowledge, the majority of research has not separated ethnicity from immigration status. The objective of the current study was to determine the impact of ethnicity, independent of immigration status, on cancer outcomes in Chinese and South Asian populations in Ontario, Canada. METHODS: The authors conducted a population-based retrospective cohort study using administrative databases in Ontario, Canada...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315507/lifestyle-factors-and-subsequent-ischemic-heart-disease-risk-after-hematopoietic-cell-transplantation
#6
Kasey J Leger, K Scott Baker, Kara L Cushing-Haugen, Mary E D Flowers, Wendy M Leisenring, Paul J Martin, Jason A Mendoza, Kerryn W Reding, Karen L Syrjala, Stephanie J Lee, Eric J Chow
BACKGROUND: The objective of this study was to evaluate whether modifiable cardiovascular risk conditions and lifestyle factors were temporally associated with an increased risk for ischemic heart disease and overall mortality in a cohort of hematopoietic cell transplantation (HCT) survivors. METHODS: HCT recipients who had survived for ≥1 year, were ≥20 years old, and had undergone transplantation between 1970 and 2010 at a transplant referral center were surveyed in 2010-2011 about cardiovascular health and lifestyle factors (n = 3833)...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315505/who-is-at-risk-after-risk-reduction
#7
EDITORIAL
Christine S Walsh
No abstract text is available yet for this article.
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315503/the-clinical-implications-of-immunogenomics-in-colorectal-cancer-a-path-for-precision-medicine
#8
REVIEW
Jenny M Riley, Ashley W Cross, Chrystal M Paulos, Mark P Rubinstein, John Wrangle, E Ramsay Camp
Colorectal cancer (CRC) remains the third most common malignancy and the second-leading cause of cancer-related deaths in the United States. Large multi-omic databases, such as The Cancer Genome Atlas and the International Colorectal Cancer Subtyping Consortium, have identified distinct molecular subtypes related to anatomy. The identification of genomic alterations in CRC is now critical because of the recent success and US Food and Drug Administration approval of pembrolizumab and nivolumab for microsatellite-instable tumors...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315500/long-term-outcome-of-dasatinib-first-line-treatment-in-gastrointestinal-stromal-tumor-a-multicenter-2-stage-phase-2-trial-swiss-group-for-clinical-cancer-research-56-07
#9
Michael Montemurro, Angela Cioffi, Julien Dômont, Piotr Rutkowski, Arnaud D Roth, Roger von Moos, Roman Inauen, Maud Toulmonde, Roger O Burkhard, Claudio Knuesli, Sebastian Bauer, Philippe Cassier, Heike Schwarb, Axel Le Cesne, Dieter Koeberle, Daniela Bärtschi, Daniel Dietrich, Christine Biaggi, John Prior, Serge Leyvraz
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually develop resistance and progress. Dasatinib is a potent inhibitor of BCR-ABL, KIT, and SRC family kinases as well as imatinib-resistant cells. In GISTs, response evaluation is routinely done using computed tomography (CT) and 18 F-fluorodeoxyglucose positron emission tomography coupled to CT (FDG-PET/CT) for early response assessment and outcome prediction...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315499/increased-pathologic-upstaging-with-rising-time-to-treatment-initiation-for-head-and-neck-cancer-a-mechanism-for-increased-mortality
#10
Roy Xiao, Matthew C Ward, Kailin Yang, David J Adelstein, Shlomo A Koyfman, Brandon L Prendes, Brian B Burkey
BACKGROUND: Time to treatment initiation (TTI) is increasing and is associated with worsening survival. In the current study, the authors sought to identify a mechanism for this relationship by assessing the effect of TTI on clinical-to-pathologic upstaging in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Using the National Cancer Data Base, the authors analyzed patients receiving definitive surgery for SCC of the oral cavity, oropharynx, larynx, and hypopharynx from 2005 through 2014...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315498/peritoneal-carcinomatosis-after-risk-reducing-surgery-in-brca1-2-mutation-carriers
#11
Marline G Harmsen, Jurgen M J Piek, Johan Bulten, Murray J Casey, Timothy R Rebbeck, Marian J Mourits, Mark H Greene, Brigitte F M Slangen, Marc van Beurden, Leon F A G Massuger, Nicoline Hoogerbrugge, Joanne A de Hullu
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed...
January 9, 2018: Cancer
https://www.readbyqxmd.com/read/29315497/health-care-disparities-among-octogenarians-and-nonagenarians-with-stage-iii-lung-cancer
#12
Richard J Cassidy, Xinyan Zhang, Jeffrey M Switchenko, Pretesh R Patel, Joseph W Shelton, Sibo Tian, Ronica H Nanda, Conor E Steuer, Rathi N Pillai, Taofeek K Owonikoko, Suresh S Ramalingam, Felix G Fernandez, Seth D Force, Theresa W Gillespie, Walter J Curran, Kristin A Higgins
BACKGROUND: To the authors' knowledge, the practice patterns for patients aged more than 80 years with stage III non-small cell lung cancer (NSCLC) is not well known. The purpose of the current study was to investigate factors predictive of and the impact on overall survival (OS) after concurrent chemoradiation (CRT) among patients aged ≥80 years with American Joint Committee on Cancer stage III NSCLC in the National Cancer Data Base (NCDB). METHODS: In the NCDB, patients aged ≥80 years who were diagnosed with stage III NSCLC from 2004 to 2013 with complete treatment records were identified...
January 8, 2018: Cancer
https://www.readbyqxmd.com/read/29313954/phase-1-2-trial-of-temsirolimus-and-sorafenib-in-the-treatment-of-patients-with-recurrent-glioblastoma-north-central-cancer-treatment-group-study-alliance-n0572
#13
David Schiff, Kurt A Jaeckle, S Keith Anderson, Evanthia Galanis, Caterina Giannini, Jan C Buckner, Phillip Stella, Patrick J Flynn, Bradley J Erickson, John F Schwerkoske, Vesna Kaluza, Erin Twohy, Janet Dancey, John Wright, Jann N Sarkaria
BACKGROUND: Mitogen-activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)-dependent signaling are hallmarks of glioblastoma. In the current study, the authors conducted a phase 1/2 study of sorafenib (an inhibitor of Raf kinase and vascular endothelial growth factor receptor 2 [VEGFR-2]) and the mTOR inhibitor temsirolimus in patients with recurrent glioblastoma. METHODS: Patients with recurrent glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide and with ≤2 prior chemotherapy regimens were eligible...
January 3, 2018: Cancer
https://www.readbyqxmd.com/read/29313945/endocrine-dysfunction-induced-by-immune-checkpoint-inhibitors-practical-recommendations-for-diagnosis-and-clinical-management
#14
REVIEW
Romualdo Barroso-Sousa, Patrick A Ott, F Stephen Hodi, Ursula B Kaiser, Sara M Tolaney, Le Min
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, because ICIs block coinhibitory molecules on T cells and other immune cells, unleashing them to mediate tumor cell killing, they also can disrupt the maintenance of immunological tolerance to self-antigens. Compared with chemotherapy, ICIs have a different toxicity profile, especially the occurrence of autoimmune-like manifestations against multiple organ systems, including endocrine glands, commonly referred to as immune-related adverse events...
January 3, 2018: Cancer
https://www.readbyqxmd.com/read/29313943/pediatric-oncologist-willingness-to-offer-germline-tp53-testing-in-osteosarcoma
#15
Eliana Shaul, Michael Roth, Yungtai Lo, David S Geller, Bang Hoang, Rui Yang, David Malkin, Richard Gorlick, Jonathan Gill
BACKGROUND: Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by mutations in the tumor-suppressor gene TP53. Osteosarcoma is a sentinel cancer in LFS. Prior studies using Sanger sequencing platforms have demonstrated that 3% of individuals with osteosarcoma harbor a mutation in TP53. New data from next-generation sequencing have demonstrated that 3.8% of patients with osteosarcoma have a known pathogenic variant, and an additional 5.7% carry exonic variants of unknown significance in TP53...
January 3, 2018: Cancer
https://www.readbyqxmd.com/read/29278461/implementing-the-paris-system-for-reporting-urinary-cytology-results-in-a-decrease-in-the-rate-of-the-atypical-category-and-an-increase-in-its-prediction-of-subsequent-high-grade-urothelial-carcinoma
#16
Yujing Wang, Manon Auger, Yonca Kanber, Derin Caglar, Fadi Brimo
BACKGROUND: In the current study, the authors evaluated the impact of implementing The Paris System for Reporting Urinary Cytology (PSRUC) on the prevalence of various cytological categories and their association with a subsequent diagnosis of high-grade urothelial carcinoma (HGUC). METHODS: A comparative study was conducted over the 6-month period before PSRUC implementation (2013), including 1653 patients and 2371 specimens versus a 6-month period after implementation of the PSRUC (2016), including 1478 patients and 2392 specimens...
December 26, 2017: Cancer
https://www.readbyqxmd.com/read/29278434/intended-and-unintended-consequences-ethics-communication-and-prognostic-disclosure-in-pediatric-oncology
#17
Jonathan M Marron, Angel M Cronin, Tammy I Kang, Jennifer W Mack
BACKGROUND: The majority of patients desire all available prognostic information, but some physicians hesitate to discuss prognosis. The objective of the current study was to examine outcomes of prognostic disclosure among the parents of children with cancer. METHODS: The authors surveyed 353 parents of children with newly diagnosed cancer at 2 tertiary cancer centers, and each child's oncologist. Using multivariable logistic regression, the authors assessed associations between parental report of elements of prognosis discussions with the oncologist (quality of information/communication and prognostic disclosure) and potential consequences of these discussions (trust, hope, peace of mind, prognostic understanding, depression, and anxiety)...
December 26, 2017: Cancer
https://www.readbyqxmd.com/read/29278433/molecular-testing-for-thyroid-nodules-review-and-current-state
#18
REVIEW
Mara Y Roth, Robert L Witt, David L Steward
Thyroid nodules affect nearly two-thirds of the world population. Fine-needle biopsy with cytologic evaluation remains the diagnostic test of choice to distinguish benign from malignant thyroid nodules yet fails to discriminate as benign or malignant in up to one-third of cases. This review discusses the limitation of current cytopathologic evaluation, the development of thyroid molecular testing, and the strengths and limitations of commercially available tests. Initial cytomolecular testing sought to identify specific gene mutations associated with thyroid cancer...
December 26, 2017: Cancer
https://www.readbyqxmd.com/read/29278431/reply-to-distinguishing-between-cisnet-model-results-versus-cisnet-models
#19
LETTER
Elizabeth Kagan Arleo, R Edward Hendrick, Mark A Helvie, Edward A Sickles
No abstract text is available yet for this article.
December 26, 2017: Cancer
https://www.readbyqxmd.com/read/29278430/distinguishing-between-cisnet-model-results-versus-cisnet-models
#20
LETTER
Donald A Berry, Harry J de Koning, Sandra J Lee, Jeanne S Mandelblatt, Sylvia K Plevritis, Clyde B Schechter, Natasha K Stout, Amy Trentham-Dietz
No abstract text is available yet for this article.
December 26, 2017: Cancer
journal
journal
20067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"